These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30802257)

  • 1. HIV treatment outcomes following antiretroviral therapy initiation and monitoring: A workplace program in Papua, Indonesia.
    Limmade Y; Fransisca L; Rodriguez-Fernandez R; Bangs MJ; Rothe C
    PLoS One; 2019; 14(2):e0212432. PubMed ID: 30802257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with immunological and virological discordant responses to highly active antiretroviral therapy among adult HIV positive individuals in Ethiopia: A cross-sectional study.
    Manaye GA; Abateneh DD; Asmare WN; Abebe M
    Medicine (Baltimore); 2021 Nov; 100(47):e27624. PubMed ID: 34964727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana.
    Obiri-Yeboah D; Pappoe F; Baidoo I; Arthur F; Hayfron-Benjamin A; Essien-Baidoo S; Kwakye-Nuako G; Ayisi Addo S
    BMC Infect Dis; 2018 May; 18(1):230. PubMed ID: 29783953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy.
    Melku M; Abebe G; Teketel A; Asrie F; Yalew A; Biadgo B; Kassa E; Damtie D; Anlay DZ
    Environ Health Prev Med; 2020 Aug; 25(1):43. PubMed ID: 32838734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia.
    Hailu GG; Hagos DG; Hagos AK; Wasihun AG; Dejene TA
    PLoS One; 2018; 13(5):e0196259. PubMed ID: 29715323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
    Rusine J; Asiimwe-Kateera B; van de Wijgert J; Boer KR; Mukantwali E; Karita E; Gasengayire A; Jurriaans S; de Jong M; Ondoa P
    PLoS One; 2013; 8(8):e64345. PubMed ID: 23950859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].
    Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM
    Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study.
    Kayigamba FR; Franke MF; Bakker MI; Rodriguez CA; Bagiruwigize E; Wit FW; Rich ML; Schim van der Loeff MF
    PLoS One; 2016; 11(7):e0159446. PubMed ID: 27438000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.
    Fielding KL; Charalambous S; Stenson AL; Pemba LF; Martin DJ; Wood R; Churchyard GJ; Grant AD
    BMC Infect Dis; 2008 Jul; 8():93. PubMed ID: 18631397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
    Sued O; Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Claramonte X; Plana M; Tuset M; Pumarola T; Gallart T; Gatell JM; Miró JM
    PLoS One; 2015; 10(7):e0131651. PubMed ID: 26186440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated With Early Virological Response in HIV-Infected Individuals Starting Antiretroviral Therapy in Brazil (2014-2015): Results From a Large HIV Surveillance Cohort.
    Meireles MV; Pascom ARP; Duarte EC
    J Acquir Immune Defic Syndr; 2018 Aug; 78(4):e19-e27. PubMed ID: 29557856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.